30/03/2026 Zymeworks' ZW191 ADC received the FDA fast track designation for PROC Elevar Therapeutics' NDA for lirafugratinib received priority review status from the FDA for cholangiocarcinoma Zymeworks' ZW191 ADC received the FDA fast track designation for PROC   ( Ref )    The US FDA granted the fast track designation to Zymeworks Inc's ZW191 (FRα-targeting ADC) for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC). Zymeworks is